Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology. Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world's largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications. Crown Bioscience's expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in …

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Valerio is a clinical-stage biotechnology company developing novel oncology drugs targeting tumor DNA-binding functions. Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on …

26 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Unlocking the potential of solid samples in the field of biological diagnostic Diagante develops a solution for in vitro diagnostics. Its platform allows the analysis of solid clinical specimen on rapid and high throughput instruments in clinical pathology labs. It provides faster results, enhanced personalized medical care, and lower costs to the stakeholders.

75 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

RNA Therapeutics We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

113 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology Data Analytics

Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle

235 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology

Preclinical CRO in Hematological Cancers Diag2Tec is an expert preclinical CRO devoted to hematological cancers, especially Multiple Myeloma (MM). We focused on in vitro Drug Testing in Human Hematological Cancer derived Cell Lines and Primary Cells from patients with various Hematologic Malignancies (Multiple Myeloma, Diffuse Large B Cells Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Mantle cell Lymphoma, Chronic Lymphoid Leukemia...). With our 2 platforms : Drug Testing Services and ChimioFx, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and phamaceutical companies to focus their drug development on …

28 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ID SOLUTIONS offers comprehensive Molecular Typing Assays using DigitalPCR for Oncology Diagnostics Our mission To provide innovative, reliable and standardized tools for oncology diagnostic. Research on circulating DNA from liquid biopsy, tumor DNA from solid biopsies. Our team is of molecular biology specialists with more than 20 years of expertise in nucleic acid extraction, molecular biology and oncology. Our proposals To offer a complete molecular typing solution, standardized operating procedures and custom development to improve diagnosis in oncology. biologie moléculaire, diagnostic oncologique, ADN circulant, biopsie liquide, PCR, Digital PCR, Multiplexing, Covid-19, and SARS-CoV-2

10 similar entities Type: Startup Activities: deeptech biotech

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

333 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Guiding clinicians towards personalized treatment and enhancing quality of life for patients Using molecular structures to choose the best therapy. Currently focusing on mutations in EGFR and other lung cancer drivers. Working closely with the Molecular Tumor Board at the UMCG #umcg and patient organizations across Europe.

65 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Cancer profiling for precision oncology and early cancer detection iCellate develops and provides cancer profiling services for precision oncology. iCellate’s CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® is an analysis for hereditary cancer and gBRCA testing. Cancer Diagnostics, Circulating Tumor Cells (CTC), Liquid Biopsy, Next Generation Sequencing, CDx, Hereditary Cancer, Early Detection, Cancer, and Solid Tumors

54 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Multiomics research for precision medicines Platinum Discovery offers a cutting-edge Tumour-to-Target Platform, specialising in cancer vaccine development through the identification of tumour-specific neoantigens. We provide a comprehensive, end-to-end drug discovery pipeline, supporting clinical trial research and translational science for patient samples. Our multidisciplinary team brings together expertise in biology, clinical sciences, multi-omics technologies, bioinformatics, and computational sciences, enabling a deep understanding of the biological processes critical to drug development. We excel at integrating diverse scientific domains to deliver holistic, innovative solutions. With extensive experience in designing and managing complex research programmes, we assemble tailored teams of experts, drawing on our …

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to make diagnostics more accurate, more informed and more accessible through proteomics of FFPEs. Dedicated to improving cancer care by developing better diagnostic assays for therapy selection. diagnostics, cancer, proteomics, biomarkers, mass spectrometry, tissue, clinical, and quality

30 similar entities Type: Startup Activities: biotech deeptech

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Empowering Therapies with Precision Data BIOMAKERS is a global Precision Medicine Company that produces complex & advanced genomic data + RWE to make cancer patients live longer and transform oncology data-driven Drug Development globally. having built an unprecedented platform that enables Diagnosis, Treatment, Drug Development, Target discovery and AI for Cancer and Rare Diseases, having developed genomic products in the 4 Stages of the Biopharmaceutical chain and providing the largest LATAM genomic representation in the global Oncology Drug Development Landscape. BIOMAKERS provides extensive genomic and molecular Testing services for cancer & rare disease patients in +17 countries in Latin America. …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I.

Oral small molecules for rare diseases Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AI-guided Functional Precision Medicine PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It’s automated microtumor-based 3DTwinTM technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome. Oncology, Combination therapies, Biotechnology, 3D tissue culture, Precision medicine, Drug profiling, Healthcare, Cancer therapy, Medtech, Life science, AI, and Personalized oncology

131 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

We bring life-saving genomics to hospitals, physicians and patients everywhere. Quantgene decentralizes genomics to bring precision medicine to everyone. Our turnkey genomics platform empowers hospitals to move life-saving genomic diagnostics inside their organizations, unlock powerful new sources of revenue and become a driving force in clinical discovery. From complete genomic profiling to hereditary cancer testing and multi-cancer early detection, we help hospitals, physicians and patients to unlock the full power of precision genomics. Cancer diagnostics, biotechnology, genomics, machine learning, oncology, precision medicine, cancer screening, deep sequencing, cancer, innovation, AI, and Cancer Detection

89 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active …

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision in Cancer Diagnostics oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics. Diagnostik, Epigenetik, Medizin, Assay Development, Diagnostics, DNA-Methylation, Medicine, and LifeScience Developments

123 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Ultra-sensitive and multiplex nucleic acid assays for fast and cost efficient mutation detection in liquid biopsy Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs. The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala …

8 similar entities Type: Startup Activities: biotech deeptech

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Genomic Vision is a French biotech providing tools and services to visualize and characterize single DNA molecules. GENOMIC VISION develops novel diagnostic and drug discovery solutions based on its world-leading nanotechnology for DNA analysis in the areas of cancer and acute diseases. These diagnostic tests and drug discovery tools operate where genome dynamics and human disease intersect. GENOMIC VISION uses a powerful technique, Molecular Combing Technology, for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. GENOMIC VISION initial focus is towards early cancer detection and …

Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Diagnostics to the Point Of Care Genedrive Diagnostics Ltd is a pharmacogenetic testing company developing and commercialising a rapid and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 …

9 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

550 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

213 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Science in Translation - We put inspiration into practice, finding viable solutions to complex challenges. Our mission is to turn scientific breakthroughs into progress for patients. TRON is a non-profit research institute that pursues new diagnostics and drugs for the treatment of cancer and other diseases with a high medical need. We aim to bridge the gap between fundamental science at universities and market-oriented research in the pharmaceutical industry. We turn innovative scientific concepts into treatments ready for clinical testing, thereby accelerating the translation of discoveries into new diagnostics and therapies for patients. We focus our transdisciplinary competencies in genomics …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing novel IVD solutions Genz is a spin-off biotech company developing novel solutions from in vitro diagnostics to therapeutics. Our mission is to deliver a consistent stream of innovative, affordable, and accessible diagnostic solutions and make a remarkable impact on people’s lives. We’re focused on sustainable growth and addressing the world’s pressing health challenges; therefore, we’re able to create value for both our patients and our shareholders. To date, Genz developed 4 IVD diagnostic tests commercially legalized, attended International joint projects, partnered with top research centers in the world and published several scientific articles in international scientific journals. Biotechnology, Genetik …

161 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Leader in Genetic Testing Services, Genomics Research and Drug Discovery Solutions MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. Our powerful genomics solutions accelerate biomarker identification and discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome Inc. has its Corporate Headquarters and a Next Generation Sequencing (NGS) lab in Foster City, California, US. MedGenome Labs is …

41 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

The RNA Platform - by analyzing RNA we can detect disease, monitor health and design the Next Generation Cures Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression’s OneRNATM test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA’s to approved therapies and clinical trials. Genomics, information, personalized medicine, personalized diagnostics, Sequencing, prognostics, bioinformatics, sample preparation, Next Generation Sequencing, Biobank, Access to biological samples, target filtering, RNA-seq, RNA sequencing, and RNASeq of FFPE samples

102 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

543 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease

160 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

170 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

The essential biodata life science partner for rare and neurodegenerative diseases CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization. Biochemical diagnostic test, Genetic diagnostic test, Rare diseases, Congenital diseases, Oncogenetics, Clinical and medical interpretation of genetic data, Next Generation …

155 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

At Lexicon, We Pioneer Medicines that Transform Patients'​ Lives Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies …

64 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology